Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 4 Completed 2 Unknown 1 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Neoplasms by Site 1 Multiple Chronic Conditions 1 Lung Neoplasms 1 Lung Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Bronchogenic 1 Bronchial Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 77 Capecitabine 59 Cyclophosphamide 54 Paclitaxel 51 Docetaxel 49 Letrozole 44 Fulvestrant 43 Lapatinib 34 Doxorubicin 31 Carboplatin 31 Vinorelbine 30 Bevacizumab 29 Anastrozole 28 pembrolizumab 25 exemestane 24 Tamoxifen 23 Gemcitabine 22 Radiotherapy 21 Albumin-Bound Paclitaxel 19 Everolimus 17 Taxes 16 Epirubicin 15 Ado-Trastuzumab Emtansine 13 130-nm albumin-bound paclitaxel 13 pertuzumab 12 palbociclib 12 liposomal doxorubicin 11 Magnetic Resonance Spectroscopy 11 Filgrastim 11 Cisplatin 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × Patient Reported Outcome Measures × Clear all

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡